|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In FIP1L1/PDGFRA-positive chronic eosinophilic leukaemia (CEL), neither the SM nor the CEL component of the disease exhibited the KIT mutation.
|
20112369 |
2010 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The murine model and the in vitro development system of FIP1L1/PDGFR alpha-positive mast cells revealed the interaction between FIP1L1/PDGFR alpha, IL-5 and stem cell factor in the development of HES/CEL/SM.
|
20523072 |
2010 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The introduction of JAK2 mutation testing has changed dramatically the diagnostic algorithms for myeloproliferative neoplasms (MPNs) but there is still a place for conventional cytogenetic analysis in the initial work-up of MPN cases, particularly as this group of myeloid disorders has been expanded to include chronic eosinophilic leukaemia and myeloid neoplasms with abnormalities of the PDGFRA, PDGFRB, and FGFR1 genes.
|
21431636 |
2011 |
|
Chronic eosinophilic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The dysregulated tyrosine kinases, D816V KIT and FIP1L1-PDGFRA, are the prototypic oncogenic lesions resulting in systemic mastocytosis (SM) and chronic eosinophilic leukemia, respectively.
|
22449623 |
2012 |
|
Chronic eosinophilic leukemia
|
0.400 |
FusionGene
|
disease |
ORPHANET |
Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL.
|
22523564 |
2012 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL.
|
22523564 |
2012 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia.
|
23621172 |
2013 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ponatinib is a pan-FIP1L1-PDGFRα inhibitor, and clinical trials are warranted to investigate its efficacy in imatinib-resistant CEL.
|
24472312 |
2014 |
|
Chronic eosinophilic leukemia
|
0.400 |
FusionGene
|
disease |
ORPHANET |
FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia: A Low-Burden Disease with Dramatic Response to Imatinib - A Report of 5 Cases from South India.
|
24764730 |
2014 |
|
Chronic eosinophilic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, S116836 is active against WT and T674I FIP1L1-PDGFRα-expressing cells, and may be a prospective agent for the treatment of HES/CEL.
|
25431951 |
2014 |
|
Chronic eosinophilic leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
FIP1L1-PDGFRA is a constitutively activated kinase described in chronic eosinophilic leukemia (CEL) and hypereosinophilic syndrome (HES).
|
25761934 |
2015 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
To our knowledge, this is the first report of a patient with GEH associated with FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
|
25923837 |
2015 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Severe Prolonged Cough as Presenting Manifestation of FIP1L1-PDGFRA+ Chronic Eosinophilic Leukaemia: A Widely Ignored Association.
|
27164940 |
2016 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
FIP1L1-PDGFRA is a leukemogenic fusion kinase that causes chronic eosinophilic leukemia.
|
27960034 |
2017 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Fip1-like1 (FIP1L1)-platelet-derived growth factor receptor alpha (PDGFRA) (F/P) oncogene can cause chronic eosinophilic leukemia (CEL), but requires IL-5 cytokine participation.
|
29029406 |
2017 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with PDGFRA-rearranged hematopoietic neoplasms typically present with chronic eosinophilic leukemia and rarely with acute myeloid leukemia or T-lymphoblastic lymphoma.
|
29505472 |
2018 |
|
Chronic eosinophilic leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compound 15i potently inhibited the proliferation of PDGFRα driving Chronic Eosinophilic Leukemia (CEL) cell line EOL-1 through strong blockage of PDGFRα mediated signaling pathways, arresting cell cycle progression, and induction of apoptosis.
|
29544149 |
2018 |
|
Chronic eosinophilic leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The clinical laboratory work-up confirmed secondary HE in 25 (20%) patients; myeloid/lymphoid neoplasms with rearrangements of PDGFRA (n = 9) or PDGFRB (n = 2) (9%); HE associated with a well-defined myeloid neoplasm in 8 (6%); and abnormal bone marrow and/or molecular genetic abnormalities consistent with chronic eosinophilic leukemia (CEL), not otherwise specified (NOS) in 21 (17%) patients.
|
30105844 |
2018 |